1. Home
  2. ALLR vs VNRX Comparison

ALLR vs VNRX Comparison

Compare ALLR & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$1.42

Market Cap

24.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLR
VNRX
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
24.5M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
ALLR
VNRX
Price
$1.30
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$9.75
$1.67
AVG Volume (30 Days)
145.6K
318.7K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
$320,000.00
$1,727,384.00
Revenue This Year
N/A
$355.66
Revenue Next Year
N/A
$849.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.04
52 Week Low
$0.77
$0.13
52 Week High
$2.35
$3.26

Technical Indicators

Market Signals
Indicator
ALLR
VNRX
Relative Strength Index (RSI) 41.98 43.27
Support Level $1.28 $1.30
Resistance Level $1.43 $1.56
Average True Range (ATR) 0.12 0.12
MACD -0.01 0.01
Stochastic Oscillator 19.41 58.97

Price Performance

Historical Comparison
ALLR
VNRX

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Share on Social Networks: